A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2025-06-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term safety of the study intervention
orforglipron as a monotherapy or in combination with oral antihyperglycemic medication.
This study includes 3 periods as follows:
- screening and lead-in period: up to 4 weeks
- treatment period: 52 weeks, including 20 weeks of dose escalation, and
- safety follow-up period: 2 weeks.